Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Current Assets (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Current Assets for 3 consecutive years, with $536.4 million as the latest value for Q4 2024.

  • On a quarterly basis, Current Assets rose 70.24% to $536.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $536.4 million, a 70.24% increase, with the full-year FY2024 number at $536.4 million, up 70.24% from a year prior.
  • Current Assets was $536.4 million for Q4 2024 at Centessa Pharmaceuticals, up from $315.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $581.2 million in Q1 2022 to a low of $315.1 million in Q4 2023.
  • A 3-year average of $419.7 million and a median of $384.3 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: plummeted 33.87% in 2023, then surged 70.24% in 2024.
  • Centessa Pharmaceuticals' Current Assets stood at $437.7 million in 2022, then dropped by 28.02% to $315.1 million in 2023, then soared by 70.24% to $536.4 million in 2024.
  • Per Business Quant, the three most recent readings for CNTA's Current Assets are $536.4 million (Q4 2024), $315.1 million (Q4 2023), and $332.5 million (Q3 2023).